ODYSSEAS KOSTAS, M.D.

Corporate Board Profile

Tech Score: 0/100

AMARIN CORP PLC\UK

Filing Date	Source Excerpt
2023-05-26	Dr. Kostas received his B.S. degree from the Massachusetts Institute of Technology and his M.D. degree from the University of Texas Southwestern Medical School. Dr. Kostas is well-qualified to serve as a member of our Board due to his significant experience in medicine, investments, operations, research and development, capital allocation, partnerships and strategic collaboration, corporate governance, corporate finance, and mergers and acquisitions.
2024-03-04	Dr. Kostas received his B.S. degree from the Massachusetts Institute of Technology and his M.D. degree from the University of Texas Southwestern Medical School. Dr. Kostas is well-qualified to serve as a member of our Board due to his significant experience in medicine, investments, operations, research and development, capital allocation, partnerships and strategic collaboration, corporate governance, corporate finance, and mergers and acquisitions.

Filing Date

Source Excerpt

2023-05-26

Dr. Kostas received his B.S. degree from the Massachusetts Institute of Technology and his M.D. degree from the University of Texas Southwestern Medical School. Dr. Kostas is well-qualified to serve as a member of our Board due to his significant experience in medicine, investments, operations, research and development, capital allocation, partnerships and strategic collaboration, corporate governance, corporate finance, and mergers and acquisitions.

2024-03-04

ENZON PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2018-06-29	Odysseas Kostas, M.D. – Dr. Kostas has been a director of our company since September 2013. ... Dr. Kostas has a B.S. from Massachusetts Institute of Technology (MIT) and an M.D. from University of Texas Southwestern Medical School. ... Dr. Kostas’ qualifications to serve as a director of our company include his service on the board of another public company, as well as his extensive experience in the biotechnology and pharmaceutical industries. Under the Amended and Restated 2013 Outside Director Compensation Plan, each non-employee director (i) receives an annual cash retainer of $30,000, (ii) for service as chair of the Finance and Audit Committee receives an additional annual cash retainer of $10,000 and (iii) for service as a non-chair member of the Finance and Audit Committee receives an additional annual cash retainer of $5,000. ... A summary of compensation paid to each of our directors during fiscal year 2017 is set forth below. Odysseas Kostas, M.D. Fees Earned or Paid in Cash ($) 35,000 Total ($) 35,000 All three current members of our Board currently constitute the Finance and Audit Committee. ... When our Board acts as the Governance and Nominating Committee, Dr. Kostas acts as the Chairman of the Governance and Nominating Committee.
2019-07-12	Odysseas Kostas, M.D. – Dr. Kostas has been a director of our Company since September 2013. ... When our Board acts as the Governance and Nominating Committee, Dr. Kostas acts as the Chairman of the Governance and Nominating Committee. ... All three current members of our Board currently constitute the Compensation Committee. ... A summary of compensation paid to each of our directors during fiscal year 2018 is set forth below. ... Odysseas Kostas, M.D. Fees Earned or Paid in Cash ($): 35,000 ... Total ($): 35,000.

Filing Date

Source Excerpt

2018-06-29

Odysseas Kostas, M.D. – Dr. Kostas has been a director of our company since September 2013. ... Dr. Kostas has a B.S. from Massachusetts Institute of Technology (MIT) and an M.D. from University of Texas Southwestern Medical School. ... Dr. Kostas’ qualifications to serve as a director of our company include his service on the board of another public company, as well as his extensive experience in the biotechnology and pharmaceutical industries. Under the Amended and Restated 2013 Outside Director Compensation Plan, each non-employee director (i) receives an annual cash retainer of $30,000, (ii) for service as chair of the Finance and Audit Committee receives an additional annual cash retainer of $10,000 and (iii) for service as a non-chair member of the Finance and Audit Committee receives an additional annual cash retainer of $5,000. ... A summary of compensation paid to each of our directors during fiscal year 2017 is set forth below. Odysseas Kostas, M.D. Fees Earned or Paid in Cash ($) 35,000 Total ($) 35,000 All three current members of our Board currently constitute the Finance and Audit Committee. ... When our Board acts as the Governance and Nominating Committee, Dr. Kostas acts as the Chairman of the Governance and Nominating Committee.

2019-07-12

Odysseas Kostas, M.D. – Dr. Kostas has been a director of our Company since September 2013. ... When our Board acts as the Governance and Nominating Committee, Dr. Kostas acts as the Chairman of the Governance and Nominating Committee. ... All three current members of our Board currently constitute the Compensation Committee. ... A summary of compensation paid to each of our directors during fiscal year 2018 is set forth below. ... Odysseas Kostas, M.D. Fees Earned or Paid in Cash ($): 35,000 ... Total ($): 35,000.

Data sourced from SEC filings. Last updated: 2025-08-30